TABLE 3.
Primary outcomes at TOC visit
| Assessment of investigator | No. (%) of CE population receiving indicated treatment:
|
No. (%) of cMITT population receiving indicated treatment:
|
||
|---|---|---|---|---|
| Ceftaroline (n = 61) | Standard therapy (n = 27) | Ceftaroline (n = 67) | Standard therapy (n = 32) | |
| Cure | 59 (96.7) | 24 (88.9) | 59 (88.1) | 26 (81.3) |
| Failure | 2 (3.3) | 3 (11.1) | 2 (3.0) | 3 (9.4) |
| Indeterminatea | NA | NA | 6 (9.0) | 3 (9.4) |
| 95% CI | 88.7-99.6 | 70.8-97.6 | 77.8-94.7 | 63.6-92.8 |
a
By definition, responses in the CE population cannot be indeterminate. NA, not applicable.